# Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy

> **NCT06373458** · PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 30 (estimated)

## Conditions studied

- Keloid

## Interventions

- **DRUG:** Ritlecitinib

## Key facts

- **NCT ID:** NCT06373458
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06373458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06373458, "Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06373458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*